Citations

Clear

34 citation(s) found for "Miller, Richard".

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas
Jethwa, Krishan R., Newman, Neil, Selfridge, J. Eva, Anker, Christopher J., Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Hallemeier, Christopher L., Jin, Zhaohui, Kim, Ed, Kennedy, Timothy, Lee, Percy, Ling, Diane C., Miller, Eric D, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Jethwa, Krishan R. , Newman, Neil B. , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Small, William , Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001347 | PMID 42622289 Get It

Objectives: Rates of locoregional recurrence and distant metastases are high following curative-intent resection for patients with localized pancreatic adenocarcinoma. Adjuvant therapies have been investigated with the intent to reduce the risk of recurrence and improve OS. The objective of this study is to update and summarize the current evidence for adjuvant therapy following surgical resection for nonmetastatic PDAC with a focus on high-level evidence and randomized controlled trials is provided. Methods: This multispecialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Using the population, intervention, comparator, outcome, timing and study design framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥25) studies published between January 1, 2013 and February 13, 2026, from Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Review, and Scopus databases. Study type and quality were assessed. Well-established RAND/UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 74 references used as evidence, 74 are categorized as therapeutic references. Study type and quality for the references were assessed, and included 31 well-designed studies (phase II randomized and phase III), 14 moderately well-designed studies that account for most common biases (matched cohort and phase II studies), 28 studies with design limitations (retrospective reviews), and 1 reference meta-analysis. Conclusions: This systematic review and guidelines provide up-to-date recommendations focusing on recent advancements for adjuvant treatment of resected PDAC using modern systemic therapy regimens and selective use of radiotherapy using modern techniques.
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer
Miller, Eric D. , Jethwa, Krishan R. , Dozois, E, Jin, Zhaohui, Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Codipilly, D Chamil, Anker, Christopher J., Hallemeier, Christopher L. , Kennedy, Timothy, Lee, Percy, Ling, Diane C., Newman, Neil, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Akselrod, Dmitriy , Dozois, Eric, Akselrod, Dmitriy , Small, William , Jethwa, Krishan , Dozois, Eric J. , Abood, Gerard, Codipilly, Don C. , Anker, Christopher J. , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Newman, Neil B. , Tchelebi, Leila T.

Mayo Clinic

Cancer | June 5, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70464 | PMID 42246062 Get It

Abstract This literature‐based systematic review and associated guidelines provide evidence‐based paradigms for the management of locoregionally recurrent rectal cancer (LRRC). This multispecialty committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and colorectal surgery. As is the standard, the previously described American Radium Society Appropriate Use Criteria methodology for this project was followed rigorously, with the Population, Intervention, Comparator, Outcome, Timing, and Study Design framework and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses methodology to assess the evidence. RAND/University of California Los Angeles consensus methodology (modified Delphi) was used to rate the appropriateness of treatment options. Published between January 1, 2013, and July 16, 2025, 116 peer‐reviewed trials provided the evidence: 10 were well‐designed randomized phase 2/3 trials, 29 were moderately well designed trials that accounted for most common biases (matched cohort and phase 2), 76 trials had design limitations (retrospective), and one was a meta‐analysis. Clinical cases were created as examples to illustrate current acceptable management of LRRC. Treatment and prognosis are influenced by prior therapy and the site(s) and extent of LRRC. The ability to achieve a margin‐negative surgical resection is the ultimate determinant of survival and local control. Preoperative systemic therapy, radiation therapy, or a combination of the two can facilitate tumor downsizing and improve the likelihood of a margin‐negative resection. An individualized multidisciplinary approach is required to ensure the best outcome. Although this review does not suggest a major alteration of current practice, it provides reassuring evidence of the importance of combined‐modality therapy.
De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis
Miller, R., Tan, Po Hong, Saleeb, Andrew, Stucky, Chee-Chee, Bagaria, Sanjay P, Gabriel, Emmanuel , Grotz, Travis E. , Wasif, Nabil , Miller, Max , Thompson, Emily , Miller, Richard Max , Thompson, Emily R , Grotz, Travis E , Gabriel, Emmanuel M , Saleeb, Andrew G. , Thompson, Emily R., Fong, Zhi Ven , Bagaria, Sanjay P.

Mayo Clinic

Journal of Surgical Oncology | April 30, 2026 | Volume: 134 | Issue: 1 | Pages: 91-100

10.1002/jso.70274 | PMID 42057320 Get It

ABSTRACT Background and Objectives NCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1–2 cm tumors remains controversial. This study compared long‐term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1–2 cm aNETs. Methods Patients with pathologically confirmed 1–2 cm aNETs treated at three Mayo Clinic sites (1972–2024) were included. Primary outcomes were recurrence and all‐cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy. Results Sixty‐five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow‐up of 6.25 years (IQR 2.44–12.63). Conclusions Among patients with 1–2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.
HSR26-199: Socioeconomic, Geographic, and Insurance-Related Disparities in Survival and Treatment Outcomes for Ocular Melanoma: A 21-Year National Inpatient Cohort Study
Miller, R., Graham, William E., Kang, Paul , Graff, Jordan M., Miller, Richard Max, Barakat, Mark

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 27, 2026 | Volume: 24 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2025.7166 | PMID 42055049 Get It

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma
Adenocarcinoma, Expert Panel Adjuvant Therapy for Treatment of Locoregional Gastric, Tchelebi, Leila T. , Jin, Zhaohui, Attallah, Joseph, Abood, G., Akselrod, Dmitriy, Codipilly, D. Chamil, Dozois, Eric J. , Hallemeier, Christopher L., Krishan, Jethwa, Kennedy, Timothy, Lee, Percy P., Ling, Diane, Newman, Neil B. , Sharma, Navesh K, Small, William, Russo, Suzanne , Tchelebi, Leila , Jin, Zhaohui , Abood, Gerard, Akselrod, Dmitriy , Anker, Christopher J. , Codipilly, Don C. , Hallemeier, Christopher Leigh , Lee, Percy , Miller, Eric D. , Sharma, Navesh, Small, William , Russo, Suzanne

Mayo Clinic

American Journal of Clinical Oncology | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001309 | PMID 41712927 Get It

Objectives: To summarize recent high-quality trials and provide an update to the original 2022 American College of Radiology Appropriate Use Criteria for Treatment of Locoregional Gastric Adenocarcinoma. This multi-specialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Methods: Using the population, intervention, comparator, outcome, timing, and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II/II trials and select retrospective studies published between 5/1/2020 and 8/1/2025 in the Embase, Medline, and Pubmed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include adjuvant FLOT chemotherapy for localized gastric adenocarcinoma after neoadjuvant FLOT and surgery, poCT or perioperative chemoimmunotherapy for localized gastric adenocarcinoma, adjuvant chemotherapy +/− CRT for localized gastric adenocarcinoma that undergoes upfront surgery, and systemic therapy alone for localized gastric adenocarcinoma in a medically inoperable patient. Conclusions: This updated ARS AUC summary provides guidelines for the multimodality treatment of resectable gastric adenocarcinoma.
Conflation of Covariate Adjustments With Causal Effects—The Table 2 Fallacy in Surgical Literature
Mah, Alexis , Miller, Richard M., Hallet, Julie H., Ven Fong, Zhi, Hallet, Julie , Fong, Zhi Ven

Mayo Clinic

Annals of Surgery | February 18, 2026 | Volume: 284 | Issue: 2 | Pages: 445-447

10.1097/sla.0000000000007034 | PMID 41703678 Get It

Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
Tan, Po Hong, Thiels, Cornelius A., Poruk, Katherine E. , Miller, R., Hor, Hoe Yan , Tu, Melody Pi Yin , Huyser, Michelle R., Stucky, Chee-Chee, Wasif, Nabil , Bold, Richard J. , Smoot, R., Starlinger, Patrick P., Warner, Susanne G., Kendrick, M., Stauffer, John A., Truty, M., Fong, Zhi Ven, _, _, Poruk, Katherine, Miller, Richard Max, Thiels, Cornelius A. , Stucky, Chee‐Chee , Starlinger, Patrick , Warner, Susanne G. , Kendrick, Michael L. , Stauffer, John , Truty, Mark J. , Fong, Zhi Ven

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 27-33

10.6004/jnccn.2025.7097 | PMID 41671431 Get It

Background: Upfront resectable pancreatic ductal adenocarcinoma (PDAC) is defined by the NCCN as disease with ≤180° portomesenteric vein (PMV) abutment. However, the clinical significance of PMV abutment in this cohort remains unexplored, and we sought to investigate its impact. Methods: This multi-institutional study included patients who underwent pancreatoduodenectomy (PD) for upfront resectable PDAC from 2002 to 2023. Patients with PDAC with ≤180° PMV abutment were compared with those without. Overall survival (OS) was compared and stratified based on whether patients underwent upfront surgery or neoadjuvant therapy (NAT). Results: Among 1,446 patients included, 521 (36.0%) had PMV abutment. Median OS for patients with PMV abutment was 28.8 months compared with 31.2 months for those without ( P =.17). In a stratified analysis of patients who underwent upfront surgery, patients with PMV abutment had worse OS (19.2 vs 27.6 months; P <.05) and lower R0 resection rates (63.1% vs 87.2%; P <.05) compared with those without. However, in patients who underwent NAT, this difference in R0 resection rate was not observed (91.4% vs 94.0%, respectively; P =.27). Furthermore, there was no significant difference in median OS with NAT (42.5 vs 51.6 months, respectively; P =.48). Conclusions: In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines
Carcinomatosis, Expert Panel Management of Peritoneal, Kennedy, Timothy J., Singh, Sareena , Abood, Gerard, Anker, Christopher J. , Akselrod, Dmitriy , Hallemeier, Christopher L. , Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Small, William , Russo, Suzanne , Carcinomatosis, Expert Panel Management of Peritoneal, Christenson, Eric, Jethwa, Krishan R. , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Tchelebi, Leila T.

Mayo Clinic

Cancer Medicine | July 22, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1002/cam4.71043 | PMID 40693544 Get It

ABSTRACT Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin. Aims To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence. Materials and Methods The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology. Results Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary. Discussion Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios. Conclusion A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer
Russo, Suzanne , Anker, Christopher J. , Codipilly, Don C. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher L. , Kennedy, Timothy J., Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Jin, Zhaohui , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Small, William , Tchelebi, Leila T. , Simone, Charles B.

Mayo Clinic

American Journal of Clinical Oncology | June 25, 2025 | Volume: 48 | Issue: 12 | Pages: 579-599

10.1097/coc.0000000000001222 | PMID 40557604 Get It

Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence. Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents. Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment. Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Gholami, Sepideh , White, Sarah B. , Wu, Christina, Goulet, Christopher C., Jee, Kyung‐Wook , Wright, Chadwick , Yaeger, Rona , Shergill, Ardaman , Hong, Theodore S. , Miller, Eric D. , Hitchcock, Kathryn E. , Shi, Qian , Dixon, Jesse G. , George, Thomas J. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Romesser, Paul B.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps3634 Get It

TPS3634 Background: For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with long-term progression-free and overall survival (OS) primarily based on retrospective evidence. However, in patients with limited metastatic CRC that is deemed inoperable or those with additional disease outside of the liver or lungs, the role of local ablative therapies, including microwave ablation (MWA) and stereotactic body radiation therapy (SBRT), to render patients disease free is less clear. Despite the long history of treating oligometastatic CRC with local therapy, which is largely provider biased, questions remain regarding the benefit of extending the paradigm of metastatic directed therapy to patients with more extensive disease. This trial seeks to use a pragmatic multimodality approach that mirrors the current clinical dilemma. This study is designed to evaluate the safety and efficacy of adding total ablative therapy (TAT) of all sites of disease to standard of care systemic treatment in those with limited metastatic CRC. Methods: A022101/NRG-GI009 is a National Clinical Trials Network randomized phase III study planned to enroll 364 patients with newly diagnosed metastatic CRC (BRAF wild-type, microsatellite stable) without peritoneal metastasis or liver-only disease on baseline imaging. Patients receive first-line systemic therapy for 12-39 weeks. Patients with ≤4 sites of metastatic disease following initial systemic therapy that are amenable to any combination of surgical resection, MWA, and/or SBRT are then randomized 1:1, stratified by number of metastatic organ sites (1-2 vs. 3-4), timing of metastatic disease diagnosis (de novo vs. secondary), and presence of metastatic disease outside the liver/lungs in at least 1 site. Patients in Arm 1 will receive TAT consisting of treatment of all metastatic sites with SBRT, MWA, and/or surgical resection followed by standard of care systemic therapy. Patients in Arm 2 will continue with standard of care systemic therapy alone. The primary endpoint is OS. Secondary endpoints include event-free survival, treatment-related toxicities, and local recurrence with exploratory biomarker analyses. The study needs 346 evaluable patients combined in the 2 arms to demonstrate an improvement in OS with a hazard ratio of 0.7 to provide 80% power with a one-sided alpha of 5%. The trial utilizes a group sequential design with two interim analyses (25% and 50% of events) for futility. The trial activated in January 2023 and recruitment is ongoing. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org. U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG); Clinical trial information: NCT05673148 .